# US 2010/0166715 A1 · T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166715 A1
- Document ID: US20100166715A1
- Status: Published application
- Kind: A1
- Application number: 12/520,699
- Filed: 2007-12-23
- Published: 2010-07-01
- Earliest claimed: 2006-12-21
- Assignees: Biokine Therapeutics Ltd.
- Inventors: Amnon Peled; Michal Begin; Katia Beider; Michal Abraham
- Web page: https://patentgrep.com/patent/US20100166715A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved.

## Claims

### Claim 1

A pharmaceutical composition comprising as active ingredients effective amounts of at least one cytokine that stimulates mobilization of hematopoietic cells and a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein the cytokine is granulocyte-colony stimulating factor (G-CSF).

### Claim 3 (depends on 1)

The composition of claim 1, wherein the analog or derivative has an amino acid sequence as set forth in formula (I) or a salt thereof:
(I)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
A1-A2-A3-Cys-Tyr-A4-A5-A6-A7-A8-A9-A10-Cys-A11
wherein:
A1 is an arginine, lysine, ornithine, citrulline, alanine or glutamic acid residue or a N-α-substituted derivative of these amino acids, or A1 is absent;
A2 represents an arginine or glutamic acid residue if A1 is present, or A2 represents an arginine or glutamic acid residue or a N-α-substituted derivative of these amino acids if A1 is absent;
A3 represents an aromatic amino acid residue;
A4, A5 and A9 each independently represents an arginine, lysine, ornithine, citrulline, alanine or glutamic acid residue;
A6 represents a proline, glycine, ornithine, lysine, alanine, citrulline, arginine or glutamic acid residue;
A7 represents a proline, glycine, ornithine, lysine, alanine, citrulline or arginine residue;
A8 represents a tyrosine, phenylalanine, alanine, naphthylalanine, citrulline or glutamic acid residue;
A10 represents a citrulline, glutamic acid, arginine or lysine residue;
A11 represents an arginine, glutamic acid, lysine or citrulline residue wherein the C-terminal carboxyl may be derivatized;
19. and the cysteine residue of the 4-position or the 13-position can form a disulfide bond, and the amino acids can be of either L or D form.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the peptide is selected from the group consisting of SEQ ID NOS:1-72.

### Claim 5

(canceled)

### Claim 6

A method for elevating the levels of at least one type of hematopoietic cells in a subject comprising administering to the subject an effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

The method of claim 6, wherein the peptide is selected from the group consisting of SEQ ID NOS:1-72.

### Claim 9 (depends on 6)

The method of claim 6 for elevating the levels of said cells in peripheral blood of a subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the peptide is administered to said subject in combination with at least one cytokine that stimulates mobilization of hematopoietic cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the peptide is administered in combination with G-CSF.

### Claim 12 (depends on 9)

The method of claim 9, wherein the hematopoietic cells are selected from hematopoietic progenitor cells, hematopoietic stem cells, mononuclear cells, mature macrophages and neutrophils.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 6)

The method of claim 6, for elevating the levels of hematopoietic precursor cells in the bone marrow of a subject suffering from or at risk of bone marrow suppression associated with exposure to radiation or chemotherapy.

### Claim 16 (depends on 15)

The method of claim 15, wherein said cells are hematopoietic progenitor cells selected from the group consisting of CFU-GEMM, BFU-E CFU-GM and CFU-M or wherein said cells are hematopoietic stem cells.

### Claim at position 17

17-19. (canceled)

### Claim 20

A method for obtaining a therapeutically effective amount of hematopoietic precursor cells from a subject, comprising:
a) administering to the subject an effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof;
b) harvesting said precursor cells by apheresis; and optionally
c) repeating steps (a) and (b) until a therapeutically effective amount of hematopoietic precursor cells is obtained.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein the peptide is selected from the group consisting of SEQ ID NOS:1-72.

### Claim 23 (depends on 20)

The method of claim 20, wherein the peptide is administered to said subject in combination with at least one cytokine that stimulates mobilization of hematopoietic cells.

### Claim 24 (depends on 23)

The method of claim 23, wherein the peptide is administered in combination with G-CSF.

### Claim 25

A method for obtaining long-term engraftment of hematopoietic precursor cells, comprising:
a) administering to a first subject an effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof;
b) harvesting said precursor cells by apheresis;
c) optionally repeating steps (a) and (b) until a therapeutically effective amount of hematopoietic precursor cells is obtained; and
d) transplanting the resulting cells to the first subject or to a second subject in need thereof.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The method of claim 25, wherein the peptide is selected from the group consisting of SEQ ID NOS:1-72.

### Claim 28 (depends on 25)

The method of claim 25, wherein the peptide is administered to said subject in combination with at least one cytokine that stimulates mobilization of hematopoietic cells.

### Claim 29 (depends on 28)

The method of claim 28, wherein the peptide is administered in combination with G-CSF.

### Claim 30

A method of increasing G-CSF-induced hematopoietic precursor cell mobilization, comprising administering to a subject an effective amount of G-CSF in concurrent or sequential combination with a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein said cells are selected from CFU-GEMM and BFU-E.

### Claim 32 (depends on 6)

A method of according to claim 6 for increasing G-CSF-induced elevation of mononuclear cell blood counts, comprising administering to a subject an effective amount of G-CSF in concurrent or sequential combination with a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 33

A method for reducing the duration of cytopenia in a subject in need thereof comprising administering to the subject an effective amount of G-CSF in concurrent or sequential combination with a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The method of claim 33, wherein the peptide is selected from the group consisting of SEQ ID NOS:1-72.

### Claim 36 (depends on 33)

The method of claim 33, for the treatment or prevention of neutropenia.

### Claim 37

A pharmaceutical kit containing: i) at least one cytokine that stimulates mobilization of hematopoietic cells and ii) a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.

### Claim 38 (depends on 37)

The kit of claim 37 containing: i) G-CSF and ii) a peptide having an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof.
